Blood · 2007 · 157 citations · 34 references
MedicineHematologyOncologyHematologic OncologyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationHematologic DisordersHematologic MalignanciesHematopoietic NeoplasmsHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TransplantationMyelodysplastic Syndrome TherapyMyelodysplastic Syndrome TreatmentMyelodysplastic Syndromes TransplantationTherapy-related Myelodysplastic SyndromesTransplantation For Hematologic MalignanciesTransplantation Outcome Assessment
We analyzed outcomes after hematopoietic cell transplantation (HCT) in 257 patients, 3 to 72.7 years old (median, 43 y), with secondary myelodysplastic syndrome (MDS) including those with transformation to acute myeloid leukemia (tAML). Conditioning regimens included high-dose total-body irradiation (TBI)/chemotherapy (n = 83); busulfan (BU)/cyclophosphamide (CY) (BUCY, n = 122; with BU targeting [tBUCY], n = 93); fludarabine (Flu) with tBU (FLUtBU; n = 12); Flu plus 200 cGy TBI (n = 26); and miscellaneous regimens (n = 14). Donors were HLA-identical or partially mismatched family members in 135 and unrelated individuals in 122 patients. Five-year relapse-free survival was highest (43%) and nonrelapse mortality lowest (28%) among tBUCY-conditioned patients. Outcomes were compared with results in 339 patients who received transplants for de novo MDS/tAML, and a multivariate analysis failed to show significant differences in outcome between the 2 cohorts. Relapse probability and relapse-free survival correlated significantly with disease stage (P < .001) and karyotype (P < .001). Relapse incidence was lower (P = .003) and relapse-free survival superior (P = .02) with unrelated donor transplants. The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied.
34
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text
Proposals for the classification of the myelodysplastic syndromes
John M. Bennett, Daniel Catovsky, MT Daniel et al. · British Journal of Haematology · 1982 · 3.7K citations
Medicine, Hematology, Pathology +12
Rainer Storb, H. Joachim Deeg, John Whitehead et al. · New England Journal of Medicine · 1986 · 1.5K citations
Medicine, Hematology, Immunology +14